BOSTON--(BUSINESS WIRE)--Foundation Medicine, Inc., a genomics company committed to transforming cancer care, today announced that it has expanded its immunohistochemistry (IHC) test offerings to ...
Complete suite of IHC testing for key biomarkers in all solid tumors, including c-MET, now available in addition to Guardant360 Tissue multiomic profiling test PALO ALTO, Calif.--(BUSINESS WIRE)-- ...
Dr Mark Kris discusses the increasing precision of lung cancer therapies and the need for additional testing to find ...
Boston Cell Standards today announced the publication of the CASI-01 study in Lancet: eBioMedicinedemonstrating that calibration dramatically improves the accuracy and reproducibility of ...
The external assessment group (EAG) did a systematic review to identify evidence on the clinical effectiveness and diagnostic accuracy of IHC- and MSI-based testing strategies for detecting Lynch ...
PALO ALTO, Calif. - Guardant Health, Inc. (NASDAQ: GH), a precision oncology company valued at approximately $5 billion, has introduced a complete suite of immunohistochemistry (IHC) testing for key ...
Exploring the Prognostic and Predictive Impact of Genomic Loss of Heterozygosity and Homologous Recombination Deficiency Alterations in Patients With Metastatic Colorectal Cancer Testing was performed ...
Unele rezultate au fost ascunse, deoarece pot fi inaccesibile pentru dvs.
Afișați rezultatele inaccesibile